Chardan Cuts Price Target For Esperion Therapeutics Inc; Here’s Why

In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ:ESPR), while reducing the price target from $55 to $40, emphasizing increased conviction in his Sell rating. The decreased price target comes after the FDA announced it approved Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s LDL-lowering anti-PCSK9 therapy, Praluent.

Amusa explained, “For ESPR, the Praluent label reveals an important set of negatives, since: (1) FDA has had an apparent policy change by, as we expected, not approving broad use for Praluent, an extremely potent add-on LDL-lowering compound, when ETC-1002’s add-on LDL-lowering ability is uncontroversially much more modest than Praluent; (2) Praluent was only approved for patients on maximally tolerated statins (MTS), while ETC-1002 has not been tested in this population in its clinical trials and to us would have negligible efficacy if it were tested with MTS given that ETC-1002 works upstream of statins; and (3) FDA did not approve Praluent for statin intolerant patients, even though Regeneron conducted and submitted to FDA a statin intolerant trial for Praluent, meaning ETC-1002 might never get this label indication.

“For these three reasons, and as a consequence of our unanswered concerns on ETC-1002’s safety (e.g. Study -008 has shown significant adverse events, SAEs, that are unexplained and also has shown high levels of unexplained drug-related adverse events in one arm) and ETC-1002’s efficacy, we now cut our ESPR price target.”, the analyst added.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Gbola Amusa MD CFA has a total average return of 19% and a 72.1% success rate. MD has a 16.8% average return when recommending ESPR, and is ranked #311 out of 3745 analysts.


While Amusa rates Esperion Therapeutics a Sell, out of 8 analysts polled by TipRanks, 7 rate the stock a Buy. With a return potential of 61.2%, the stock’s consensus target price stands at $117.75.


ESPR Chart

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts